Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Nascent Pharma Holdings's accounts receivables for the quarter that ended in Sep. 2024 was $1.42 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Nascent Pharma Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2024 was 8,638.33.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Nascent Pharma Holdings's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-0.27.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Nascent Pharma Holdings's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Nascent Pharma Holdings's accounts receivable are only considered to be worth 75% of book value:
Nascent Pharma Holdings's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Nascent Pharma Holdings Accounts Receivable Related Terms
Nascent Pharma Holdings Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Nascent Pharma Holdings's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $1.42 Mil mean?
Nascent Pharma Holdings (NASC) has a Accounts Receivable of $1.42 Mil as of Sep. 2024. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Accounts Receivable too high?
Nascent Pharma Holdings' current Accounts Receivable is $1.42 Mil. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Accounts Receivable compare to ALID and CPMD?
Nascent Pharma Holdings' Accounts Receivable of $1.42 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Drug Manufacturers company?
A good Accounts Receivable depends on the Drug Manufacturers industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Nascent Pharma Holdings and its competitors. Nascent Pharma Holdings's current Accounts Receivable is $1.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Accounts Receivable of $1.42 Mil. The current Accounts Receivable is $1.42 Mil. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Accounts Receivable is $1.42 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score
Get the complete analysis for NASC
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NASC has been successfully added to your 
